Home › Research › Drug development
[Causal treatment of Alzheimer's disease: amyloid antibodies]
Pawlowski M, Warnecke T.. Innere Medizin (Heidelberg, Germany), 2022-03-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease (AD) is the most common cause of dementia. The number of people affected will increase dramatically in the coming decades due to the demographic change. Causal pharmacological approaches have not been available to date.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that causal pharmacological approaches for Alzheimer's disease have not been available to date. It notes that aducanumab was recently approved in the USA but was rejected in Europe in December 2021 by the European Medicines Agency.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pawlowski, M., & Warnecke, T. (2022). [Causal treatment of Alzheimer's disease: amyloid antibodies]. Innere Medizin (Heidelberg, Germany). https://doi.org/10.1007/s00108-022-01291-2
Vancouver
Pawlowski M, Warnecke T. [Causal treatment of Alzheimer's disease: amyloid antibodies]. Innere Medizin (Heidelberg, Germany). 2022. doi:10.1007/s00108-022-01291-2. PMID: 35290498.
BibTeX
@article{pawlowski2022-35290498,
author = {Pawlowski, M. and Warnecke, T.},
title = {{[Causal treatment of Alzheimer's disease: amyloid antibodies]}},
journal = {Innere Medizin (Heidelberg, Germany)},
year = {2022},
doi = {10.1007/s00108-022-01291-2},
pmid = {35290498},
url = {https://doi.org/10.1007/s00108-022-01291-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The number of people affected will increase dramatically in the coming decades due to the demographic change.
- Causal pharmacological approaches have not been available to date.
- The monoclonal anti-amyloid beta antibody aducanumab was recently approved for the treatment of AD in the USA but was rejected in Europe in December 2021 by the European Medicines Agency (EMA).
- Objective This review presents the background and rationale for amyloid beta-directed treatment approaches in AD.
Why it matters
This review states that causal pharmacological approaches for Alzheimer's disease have not been available to date. It notes that aducanumab was recently approved in the USA but was rejected in Europe in December 2021 by the European Medicines Agency.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 30 of the 96 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Innere Medizin (Heidelberg, Germany)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 1 / 6 | Cited 0.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Tobias Warnecke: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Münster: institution h-index 833 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35290498) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 96 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Related studies in Drug development from nearby years
Also in Drug development
104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.